June 11, 2020 09:21 AM EDTUpdated 11:55 AM
Deals
R&D

It's all about the heart: Di­a­betes ma­jor No­vo Nordisk bets $725M up­front to buy car­dio-fo­cused As­traZeneca spin­off

Natalie Grover

Reporter

No­vo Nordisk’s itch to ex­pand its reach be­yond its main­stay di­a­betes busi­ness has man­i­fest­ed in the com­pa­ny test­ing some of its ex­ist­ing treat­ments for use …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times